BMS-201620: a selective beta 3 agonist

William N. Washburn(Bristol-Myers Squibb (United States)), Andrea A. Seymour(Bristol-Myers Squibb (United States)), Z. Merchant(Bristol-Myers Squibb (United States)), David A. Young(Newcastle University), Gregory S. Bisacchi(Bristol-Myers Squibb (United States)), M. Morella(Bristol-Myers Squibb (United States)), G.T. Allen(Bristol-Myers Squibb (United States)), Tamara Dejneka(Bristol-Myers Squibb (United States)), Peter T. W. Cheng(Bristol-Myers Squibb (United States)), Kathleen M. Poss(Bristol-Myers Squibb (United States)), Dorothy Slusarchyk(Bristol-Myers Squibb (United States)), T.C. Wang(Bristol-Myers Squibb (United States)), Benoni E. Abboa‐Offei(Bristol-Myers Squibb (United States)), Michael Cap, Amarendra B. Mikkilineni(Bristol-Myers Squibb (United States)), R.J. George(Bristol-Myers Squibb (United States)), Belay Tesfamariam(Bristol-Myers Squibb (United States)), Peggy J. McCann(Bristol-Myers Squibb (United States)), Cynthia Arbeeny(Sanofi (France)), Denis E. Ryono(Institut des Maladies Métaboliques et Cardiovasculaires), Anita D. Russell, Philip M. Sher(Bristol-Myers Squibb (United States)), B.H. Frohlich(Bristol-Myers Squibb (United States)), S. Skwish(Bristol-Myers Squibb (United States)), R.N. Girotra(Bristol-Myers Squibb (United States)), Thomas L. Waldron(Bristol-Myers Squibb (United States)), G. Wu(Guizhou University), Kenneth E.J. Dickinson(Bristol-Myers Squibb (United States)), Timothy W. Harper(Bristol-Myers Squibb (United States)), C Sun(Bristol-Myers Squibb (United States)), Ashvinikumar V. Gavai(Bristol-Myers Squibb (United States))
Bioorganic & Medicinal Chemistry Letters
May 29, 2004
Cited by 16


Related Papers